Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NCT02752685Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jun 2016
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in breast cancer (3 arms), sponsored by NYU Langone Health. Primary endpoint: Best Overall Response Rate. Started Jun 2016; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02752685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752685.